Video

Session 5: TNBC

TNBC By Rejiv Rajendranath

Chairpersons :

S H Advani, S Hukku

Speaker :

Rejiv Rajendranath

Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR triple negative breast cancer (TNBC)

Author: T. A. Traina

Conference:ASCO

Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), anandrogen receptor (AR) signaling inhibitor, in AR+ advanced triple negative breast cancer (aTNBC)

Author: J. Cortes

Conference: ESMO

Phase III trial of etirinotecan pegol (EP) versus treatment of physician’s choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine : The BEACON Study

Author: E.A. Perez

Conference: ASCO